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ABSTRACT 
The recently classified neglected tropical diseases (NTD), - onchocerciasis, 
lymphatic filariasis , schistosomiasis, and soil-transmitted helminthiasis- are all co-
endemic in Nigeria. The World Health Organization recommended strategy for 
addressing these diseases is preventive chemotherapy through annual mass drug 
administration (MDA) with ivermectin, albendazole, and praziquantel. Integrated 
delivery of these medicines has become the de facto strategy advocated for in the 
literature as a means of reducing costs through shared resources. Little empirical 
evidence, however, exists to support this. This paper explores these diseases and the 
concept of integration in the context of the global strategies for their control. 
A literature review was conducted using PubMed to identify articles published 
containing any of the disease names and costs. Ofthe 2,028 ruiicles returned, only 14 
IV 
published between 1998 and 2011 met the criteria for review. All costs were adjusted for 
inflation. Overall, the mean cost ofMDA by any means was 0.83 cents. No data 
comparing separate MDA to integrated MDA were found. To examine this, a model was 
created comparing MDA programs with similar distribution strategies and targeting 
similar diseases. Data from separate articles presenting stand alone MDA were combined 
to give a mean cost of 0.42 cents to deliver two medicines in two rounds. This was 
compared with articles showing integrated MDA, which gave a mean cost of 0.25 cents 
to deliver two medicines in a single round. This suggests a cost savings of 40 percent. 
To verify this, data from a NTD program in Nigeria that transitioned to integrated 
MDA was examined in detail. In 2008, eight districts received a single round of 
ivermectin with albendazole followed at least 1 week later by a single round of 
praziquantel to school-aged children. The following year, a single round of all three 
drugs was co-administered. The number of treated individuals was essentially unchanged 
during both years (1,301,864 in 2008 and 1,297,509 in 2009). The total programmatic 
costs for the MDA, not including drug and overhead costs, reduced by 41% from 
$123,624 to $72,870, similar to savings seen in the literature review. Cost savings were 
attributed largely to transportation and personnel costs. 
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Summary 
The scope and scale of programs to address the recently classified "neglected 
tropical diseases" (NTDs)1•2•3 have increased in recent years but the funding resources 
available to address these diseases have lagged far behind those for malaria, HIV I AIDS, 
and tuberculosis.4 In an effort to decrease costs while increasing the populations covered 
by NTD control programs, integrated delivery of interventions has been widely 
promoted.5•6•7•8 The premise behind this approach is that in countries where diseases are 
co-endemic and share similar intervention strategies, most notably mass drug 
administration (MDA), integrated delivery of programs can stretch limited resources 
further. There is little empirical evidence, however, of where these cost savings might be 
seen or what the cost profile of such a program might look like. Integrated delivery of 
the medicines ivermectin, albendazole, and praziquantel for treatment of the NTDs 
onchocerciasis, lymphatic filariasis (LF), soil transmitted helminthiasis (STH), and 
schistosomiasis has recently been shown to be safe and effective but their use and 
1. . . . h th . 9 10 11 u k f hi h app 1cat10n m preventive c emo erapy vanes. ' ' pta e o t s strategy as been 
slow and continuing concerns about safety and effectiveness as well as costs and human 
resources remain.12 This paper examines the integrated delivery of these medicines by 
first examining the diseases, their etiology, and global strategies to address them in order 
to clarify how integration occurs; second, by examining the existing literature to 
determine what the costs of drug delivery are and what savings are or should 
(theoretically) be achieved through integration; and third, presenting the results of 
research conducted on an existing program that moved from a vertical distribution system 
1 
to an integrated one. This research examines the cost of moving from one delivery 
strategy to another and identifies the major cost drivers and how they change with 
integration. It also measures the effectiveness of integration in terms of achieving 
treatment goals and safety of co-administration. The aim of the paper is to demonstrate 
the cost savings achieved through integration and its safety and effectiveness. The 
purpose of this paper is as a tool for program planning, in particular, to support scaling up 
the delivery of medicines. 
Introduction 
NTDs, referred to as the "other diseases" in the World Health Organization's 
(WHO) Millennium Development Goal 6 (MDG 6), are a group of diseases for which 
safe and effective interventions exist but which have received comparatively little support 
in the wake ofthe global attention given to HIV/AIDS, malaria, and tuberculosis. These 
diseases are among the most common infections of the world' s poor, with evidence that 
their global burden is as great or greater than any other disease. They are both a cause and 
an effect of chronic disability and poverty in low and middle income countries. 1 ·5·13 
Recent estimates have placed the combined global burden ofNTDs at 56.6 Disability 
Adjusted Life Years (DALY s) 1 , though experts argue that this number underestimates 
the true burden. 12 Despite this, fmancial support for control and elimination efforts, as 
well as for research and development, has fallen far short of what is needed. 4' 14 
1 Disability Adjusted Life Years (DALY s) are an estimate of disease burden that is the 
sum of years oflife lost to an early death plus the years lost to disability. 
2 
To address the shortcomings of support for NTD program implementation, 
integrated delivery ofNTD programs has become the de facto option called for by the 
international community. 13' 15' 16 In 2006, for example, the WHO released the guidelines, 
"Preventive Chemotherapy in Human Helminthiasis: Coordinated Use for Anthelminthic 
in Control Interventions", in which they advocated for integrated control efforts for 
several NTDS including those covered in this report. 17 The logic behind this approach is 
that in areas where NTDs are co-endemic and programs share similar intervention 
strategies, integration provides an efficient means of delivering treatment and prevention. 
Experiential evidence in support of this approach has been seen in the WHO/UNICEF 
Integrated Management of Childhood Illness (IMCI) programs of the 1990s. For NTDs, 
however, there is little evidence in the peer-reviewed literature of the effectiveness of this 
strategy, particularly in terms of costs and cost savings. 
As will be discussed in section 1 of this paper, while there is a logic that exists in 
terms of integrated NTD management, there are challenges as well. In Africa, many 
NTD programs have divergent goals: dracunculiasis (Guinea worm), for example, is an 
eradication program dependent on improving human behavior around drinking water 
while leishmaniasis is a control program which focuses on vector management and 
treatment with anti-parasitic drugs. Such differences can affect not only the treatment 
and monitoring strategies but the long-term sustainability of a program as well. Other 
diseases, such as STH and trachoma, have different mapping protocols that target 
different social units (i.e. school vs. community vs. district) and use specialized tools and 
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thresholds for treatment for many NTDs. Similarly, monitoring and evaluation strategies 
have different levels of implementation and often use different populations to determine 
success (i.e. children vs. adults). All of this is complicated by the fact that the strategies, 
goals, and tools used to assess, treat, and monitor NTDs are still evolving and changes to 
one disease protocol or another occur nearly annually. In the last five years alone, the 
protocols for schistosomiasis, trachoma, LF, and onchocerciasis have all undergone 
separate strategic changes and some are likely to change again in the coming years. 
Research into how the various levels of implementation might be integrated is 
ongoing and some evidence has shown that certain aspects ofNTD control can be 
integrated. Integrated mapping, for example, has been shown to be feasible for some 
NTDs. 18,19 Global protocols set by the WHO and used to determine drug donation policy, 
however, are still lagging behind this research and conflict with integrated mapping 
practices. For example, schistosomiasis transmission is highly localized and requires 
community level assessment to detennine implementation practices. Trachoma, on the 
other hand, is more broadly distributed and relies on district level assessments. Recent 
work by King et al. (2009) found that community level assessments for trachoma, 
integrated with schistosomiasis assessments, were more sensitive and identified 
communities eligible for trachoma treatment that would have been missed using the 
standard district level assessment. 18 Despite this, the protocols so far remain unchanged. 
Cost savings and improved impact have been a key argument in the call for 
integrated NTD programs. 6'7'8 Evaluation of costs and cost drivers (i.e. those costs that 
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move costs up or down) is a key component to understanding the benefits and limitations 
of integration. By combining strategies for disease control or elimination it is possible to 
reduce redundancy and increase capacity while simultaneously improving costs. A 
fundamental part to understanding these improvements will be the development of a cost 
profile that identifies key cost drivers, both in terms of inputs and activities, and can be 
used to identify how costs change as integration occurs. This will help in program 
management and planning by providing a clear understanding of the activities conducted 
and the support needed to carry them through in order to determine where resources need 
to be allocated. 
In the states of Plateau and Nasarawa in Nigeria, onchocerciasis, LF, STH and 
schistosomiasis are co-endemic. Since 2003, ivermectin and albendazole have been 
distributed by volunteer health workers in all30 districts within the two states to 
everyone aged 5 and above. In 2008, eight districts began schistosomiasis programs to 
treat all school aged children aged 5 to 15 with praziquantel. In 2009 these programs 
became fully integrated and all three medicines were co-administered as a single 
treatment. This transition presented an opportunity to examine how the cost structures of 
these programs changed as they moved from separate to combined treatment campaigns. 
It has also allowed both the safety and effectiveness of the community based programs to 
be assessed at scale. 
Importance 
Integration ofNTD programs and integrated delivery ofMDA have been and 
5 
continue to be the subject of numerous publications and are key components ofthe WHO 
. 112o212223 A d. h WHOp · preventive chemotherapy strategy. ' ' ' ' ccor mg tot e reventlve 
Chemotherapy Databank, the diseases onchocerciasis, LF, STH, and schistosomiasis are 
co-endemic in at least 16 countries in Africa alone?4 Although co-administration of 
ivermectin, albendazole, and praziquantel has been approved since 2006, only four 
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resources, apathy, and safety have all been cited as reasons for poor implementation of 
integrated NTD programs in general. 12 This report will provide evidence that integrated 
MDA can simultaneously reduce costs and labor while being safe and effective. 
There are two reasons why this work is important. First, analyzing the costs of 
implementing interventions is needed for the economic evaluation. Cost analysis is an 
essential part of budgeting and developing cost projections, replicating strategies, and in 
assessing priorities within programs. As will be discussed, the amount of information on 
the costs for NTD programs available in previous literature is limited, at best, and 
virtually non-existent in terms of integrated NTD strategies. Furthermore, prior to the 
study that underlies this report, details from previous studies are largely devoid of 
information on costs and cost drivers and are mostly limited to costs per treatment. 
Second, despite the recognition of these diseases as neglected, there are still 
insufficient resources available to address these diseases. As funding becomes available, 
donors and program planners need to recognize the approach that provides the greatest 
impact. That is to say, if the cost ofMDA could be reduced by 50%, then the number of 
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persons treated could similarly increase by 50%. While support for NTDs has grown in 
recent years, the prospects of achieving such support as is given to HIV/AIDS, malaria, 
or tuberculosis is still far from likely. It is therefore important to apply the available 
resources in a manner so as to ensure the greatest impact. This paper will provide the 
empirical evidence needed to show that integrated program delivery can achieve a greater 
health impact for a given level of support. 
Background 
Mass drug administration (MDA), large-scale preventive chemotherapy, is one of 
the approaches to disease control that has been highlighted by the WHO as an area where 
integration can easily be achieved. In 2006, The WHO released its guidelines for 
Preventive Chemotherapy in Human Helminthiasis. 17 These guidelines laid out the 
criteria for integrating MDA programs which target the helminthic infections: LF, 
onchocerciasis, schistosomiasis, and STH. The strategy for treating these diseases uses 
the anti-helminthic drugs ivermectin, albendazole, and praziquantel, either alone or in 
combination, to reduce morbidity or provide sustained suppression of transmission. 
When these guidelines were released, however, praziquantel was not approved for co-
administration with ivermectin and albendazole. Tllis meant that integration was limited, 
allowing only for the use of the same distribution infrastructure but still requiring a 
separate, stand-alone distribution from other MDA. 
The safety of co-administration of the drugs ivermectin, albendazole, and 
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praziquantel has been known for some time. In 2006, a study among uninfected 
individuals in Thailand showed no clinically relevant pharmacokinetic interactions or 
adverse reactions when the drugs were taken together compared to when given 
separately.9 Shortly thereafter, a large-scale trial of triple drug therapy was carried out in 
Zanzibar in which treatment was given safely to at-risk and infected persons. The study 
noted that the side effects of treatment were only "mild and selflirniting events"?7 In 
2006, a smaller study by Eigege et al. (2008) in Nigeria showed the safety of co-
administration to 5,084 persons using a community volunteer distribution structure. 11 
The study, which provided all three medicines to both children and adults, found that 
1.1% of persons treated complaining of mild adverse events after taking the three drugs, 
and that volunteer distributors only committed a 0.06% error in dosing. The following 
year, 813 ,077 co-administered treatments were successfully provided without any 
significant change in adverse events. The program now has a cumulative total of 2.04 
million treatments without any reports of serious adverse events. 
In Plateau and Nasarawa states in north-central Nigeria, integration ofNTD 
programs for LF, onchocerciasis, schistosomiasis, and STH has been ongoing since 
2000.28,1 5 Starting with integrated training and mobilization, the programs have worked 
to combine intervention activities where possible.29 In 2008, both states began to scale 
up co-administration of the drugs ivermectin, albendazole, and praziquantel. Beginning 
with a single round of separate, stand alone treatments, the two states introduced what has 
come to be known as triple drug administration (TDA). By introducing praziquantel to 
8 
/ 
an already established program to treat onchocerciasis, LF, and STH, the Ministry of 
Health (MoH) program was able to scale up from a few thousand praziquantel treatments 
in 2007 to roughly one million annually by 2009. Beginning with separate treatment 
rounds in 2008 (ivermectin and albendazole in one and praziquantel in the other), the 
program was able to co-administer all three medicines in 2009 using village volunteers 
that were part of the established community directed treatment strategy used by the 
onchocerciasis program. 
Questions and aims 
The aim of this research is to assess how integration occurs within the global 
NTD context and to examine how program costs, the structure of costs, and outputs 
evolved as an actual program evolved from two related MDA programs to one integrated 
and co-administered program (TDA). Such information remains vital for understanding 
how improvements in program delivery are made through integration. 
This paper also seeks to ascertain the effectiveness, i.e. the ability to maintain 
treatment goals, of the community directed distribution strategy with the goal of 
promoting greater use of integrated MDA in NTD programs. The paper addresses the 
following questions: 
1. What are the characteristics of the diseases in question, the global 
strategies to address them, and what is meant by integration? 
2. What does the available literature say about costs of MDA and what 
9 
savings can be expected through integration? 
3. What were the annual costs of conducting all activities related to MDA 
during the 2008 when the MDA program was not integrated and during 2009 when the 
program was integrated (IDA)? 
4. What are key cost drivers and how are these costs distributed across 
different activities related to MDA? 
5. How do total costs and the structure of costs (based on the use of inputs) 
change with integration, and are total costs reduced through integration of the programs? 
6. Does integration change the ability to maintain treatment goals ofMDA or 
the occurrence of adverse or severe adverse events? 
The paper is divided into three sections. First, there is a discussion ofthe diseases, 
LF, onchocerciasis, schistosomiasis, and STH, describing the scope and scale of the 
infections and the global strategies used to address them and what is meant by 
integration. Second, is a review of the existing literature showing the costs ofMDA for 
anti-helminthics and integrated delivery of medicines using a model for estimating 
integration savings. Third, is an analysis of actual program costs examining them as they 
transition from stand-alone to integrated delivery. 
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1. Helminth infections: scope and scale 
NTDs affect more than one billion people worldwide, primarily in Africa, Asia, 
and the Americas. Many of these diseases are "tool ready" meaning that safe and 
effective treatments exist but ~e not available to the more than 2.5 billion people living 
on less than two dollars a day who are at risk of infection. Estimates of the impact of 
these diseases suggest that more than half a million people die annually as a direct result 
of bacterial or parasitic NTDs.30 The WHO now recognizes 15 neglected diseases and 
three "neglected conditions" (Annex 1). Despite the significant burden of these diseases 
and the availability of medicines to treat or prevent infection, the majority of those at risk 
do not have the means or resources to receive treatment. 
Onchocerciasis, LF, STH, and schistosomiasis are all NTDs for which safe and 
effective treatments exist. They belong to a class of parasitic worms call helminths. The 
word helminth is derived from the Greek word helmin meaning "worm" and is used to 
classify a wide range of parasitic worms found in human and animal populations around 
the world. While these diseases share a common lineage, the causative agents, modes of 
transmission, and clinical manifestations vary. Onchocerciasis, a leading cause of visual 
impaitment and blindness in many developing countries, is caused by Onchocerca 
volvulus, and is transmitted through the bite of Simulium species of black fly. Lymphatic 
filariasis (LF), a chronic parasitic infection caused by Wuchereria bancrofti, Brugia 
malayi, or Brugia timori, is transmitted by mosquitoes, and causes swelling of limbs and 
genital organs (lymphedema, elephantiasis and male hydrocele) and painful, recurrent, 
11 
debilitating attacks of acute adenolymphangitis. Soil transmitted helminths are any of 
several intestinal nematodes: Ascaris lumbricoides, Trichuris trichiura, Ancylostoma 
duodenale, or Necator americanus and are among the most common infections world-
wide causing widespread anemia, stunted growth, nutritional deficits, and general 
weakness that can affect learning and work. Schistosomiasis is a trematode infection 
transmitted to humans through contact with contaminated water. Chronic disease can 
result in anemia, stunted growth, and poor school or work performance and can lead to 
bladder fibrosis, cancer, and complications associated with portal hypertension. 
1.1 Onchocerciasis 
Characteristics & Transmission 
Onchocerciasis is a leading cause of visual impairment and blindness in many 
developing countries. The main complications of infection are severe eye disease, which 
leads to blindness, and skin disease characterized by lesions and intense, burning itching. 
These lesions give rise to the characteristic white spots known as "leopard skin" seen on 
many people who are chronically infected. 0. volvulus is transmitted through the bite of 
the Simulium species of black fly whose larvae grow in fast flowing streams and rivers 
that has given rise to the diseases' more common name of"River Blindness." In Africa, 
the most common black fly vectors for onchocerciasis are S. damnosum found throughout 
the continent and S. neavei found primarily in East Mrica. 
Onchocerciasis is transmitted when a black fly takes a blood meal containing 0. 
volvulus larvae, called microfilariae. Once the black fly is infected, the larvae then pass 
12 
through several developmental stages designated as L1, L2, and L3. Once the infective 
L3 stage is reached, the larvae migrate to the mouth of the black fly and are transmitted to 
another human host when bitten. Once in the human host, larvae reach adulthood after 
about one year and can live as long as 15 years. Once mature, the adult worms often 
become entwined with other Onchocerca worms forming nodules where they mate, 
producing thousands of micro filariae, which then migrate through the skin, eyes, and 
other organs. These nodules are often visible under the skin and were used historically as 
an early indication of onchocerciasis infection. 
The majority of micro filariae that are not taken up by a black fly die within one to 
two years. Depending on the location in the body, the presence of the dead microfilariae 
initiates an immune response causing damage to the infected organs: dead microfilariae 
in the skin can cause "leopard skin," while infections in the eye cause inflammation 
which leads to irreversible ocular lesions that causes first, visual impairment, and 
eventually, blindness. 
Disease Burden 
Onchocerciasis is endemic in 30 countries in Africa, 6 in the Americas, and 
Yemen in the Arab Peninsula. There are an estimated 3 7 million people infected with 
onchocerciasis and 120 million at risk of infection globally.3 1 The WHO estimates that 
of those infected, 270,000 are blind and half a million suffer from some form of visual 
impairment. 
Persons who leave near fast flowing rivers or streams are at the greatest risk for 
13 
infection. Both S. damnosum and S. neavei have limited flight ranges though S. 
damnosum is more robust and able to travel farther than S. neavei. Chronic 
contamination through multiple bites is usually needed to cause infection such that those 
who travel to endemic areas for periods of less than three months have a relatively low 
risk of infection. 
Identification 
Historically, infection with onchocerciasis was determined by the outward 
symptoms of the disease. Nodule rates, the number of persons affected with visible 
Onchocerca nodules, was an early indicator of the level of infection in endemic 
communities and was used by the WHO to map the disease during the 1980s and 90s. 
Skin snips, small bits of tissue which can be examined for presence of micro filariae, have 
since become a more accurate diagnostic tool for assessing the presence of onchocerciasis 
as nodules can take years to develop and are not necessarily present on everyone who is 
infected. Antigen tests have also recently been improved to detect the presence of 
antibodies to the OV-16 antigen. These tests are highly sensitive to the presence of 
antigens but will detect infection with the disease even after it is no longer in the body. 
These tests are often used to measure the presence of antibodies in young children, as 
their absence would indicate that the disease is no longer being transmitted. 
Entomology is also used to identify transmission. Blackflies are examined for the 




Early treatment of onchocerciasis was through intravenous injection of the 
compound suramin sodium. Developed by Bayer in 1916, this was given once a week for 
six weeks and produced frequent nausea and vomiting as well as rash. There was also a 
high likelihood of damage to the adrenal cortex. Although this was the primary method 
of treatment into the latter half of the 20th century, because of the severe effects ofthe 
drug, treatment was reserved for only severe cases.32 For this reason, many early 
interventions focused on control ofthe black fly vector. In 1974, the WHO established 
the Onchocerciasis Control Program in West Africa (OCP). The goal of the OCP was to 
eliminate onchocerciasis in 11 countries using aerial spraying to kill the black fly vector. 
During the 1980's, a new veterinary drug called ivermectin was being used in 
many parts of the world to combat animal helminths. In areas where the drug was in use, 
Onchocerca cervicalis, a close relative of 0. volvulus that infects horses, had virtually 
disappeared. This led researchers to focus on use of the drug in humans for use against 
onchocerciasis. It was found that the drug had a microfilaricidal effect on 0. volvulus, 
killing off circulating microfilaria, but it was not clear if the drug had any 
macrofilaricidal effect that could kill adult worms which would be needed to clear the 
disease from infected individuals. In 1987, the drug was approved for human use.33 
That same year, realizing the tremendous public health benefit of the new drug, Merck & 
Co., the manufacturer ofMectizan (the brand name ofivermectin) pledged to donate the 
drug, free of charge, for as long as needed for onchocerciasis control. By 1988, 
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ivermectin had been added to the OCP's control strategy and mobile teams of health 
workers were brought on board to distribute the drug in endemic areas through MDA 
campaigns. While expensive, this proved highly successful and by 2002, the final year of 
operation of the OCP, the program had eliminated onchocerciasis in 10 of the 11 
countries targeted (Sierra Leone being the only country not to finish due to a decade long 
civil war). 
Ivermectin is now the principal tool for controlling morbidity caused by 
onchocerciasis. The African Program for Onchocerciasis Control (APOC), funded by the 
World Bank and supported by WHO, has been the organizing facilitator of control 
programs in Africa. In the Americas, the Onchocerciasis Elimination Program of the 
Americas (OEP A), a branch of P AHO, is the principal organization responsible for 
coordinating elimination efforts. 
1.2 Lymphatic filariasis (LF) 
Characteristics & Transmission 
LF is a painful, disfiguring, and debilitating disease caused by thread-like, 
parasitic filarial worms, which infect the lymphatic system. The most outwardly visible 
signs of LF are lymphedema, elephantiasis, and hydrocele of the limbs, breast, and 
genitalia. There are 8 known filarial worms that infect humans, 3 of which cause LF. B. 
malayi and B. timori are confined to Southeast Asia while W bancrofti is the most 
prevalent and can be found in Africa, India, Southeast Asia, the Pacific Islands, and parts 
of the Caribbean. 
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LF is transmitted by several types of mosquitoes, including Anopheline, Culex, 
Mansonia and Aedes species. Like onchocerciasis, micro filariae are passed to the 
mosquito when a blood meal is taken. Once in the intermediate mosquito host, the 
microfilariae develop into an infective stage, which is then passed into a new human host 
when bitten. Over the course of a year, the infective larvae travel to the lymphatic 
vessels where they develop into adult worms. The lymphatic system is pmi of the 
immune system and is comprised of a series of channels or conduits that carry a clear 
fluid called "lymph". When adult worms mate, the females produce thousands of 
microfilariae. These microfilariae are found in organs and appear in the peripheral blood 
at night during the time when mosquitoes are most active. 
In some cases, the host immune system reacts violently to the death or damage of 
adult worms causing scaning of the lymph channels. This scarring, in turn, can block the 
channels causing the lymph fluid to back up. The presence of worms in the scrotal area 
can lead to the development of hydrocele while lymphatic dysfunction caused by 
infection makes the patient more prone to repeat bacterial infections, which in turn can 
lead to lymphedema and elephantiasis. 
Disease Burden 
LF infects and estimated 120 million people in 83 countries with more than 1.2 
billion people at risk of infection. The WHO estimates that as many as 40 million 
individuals are disfigured and incapacitated by the disease. Because of the multiplicity of 
mosquito vectors, everyone living in endemic areas is considered at risk of infection. 
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Like onchocerciasis, however, multiple bites are required, with some estimates in the 
hundreds to thousands, to cause LF.34 
Identification 
Many people infected with LF are asymptomatic and diagnosis has historically 
been done by examining blood smears taken at night when the microfilariae are most 
active. While these blood tests are still used, more sensitive antibody tests for adult 
worms are now available (Og4C3 antigen test and ICT card test for antigens), although 
some have questioned their validity in long-term infections.35 
Entomology of the mosquito vector is also used to identify active transmission of 
the disease. Like onchocerciasis, the presence of L3 larvae in the mosquito indicates 
ongoing transmission. 
Treatment 
Early control strategies for LF focused on reducing microfilariae in infected 
individuals. Current efforts focus on reducing microfilariae in communities to levels low 
enough to prevent transmission. MDA campaigns focus on holding microfilariae levels 
below the threshold to have an effect on transmission. The critical threshold below 
which transmission will no longer occur is not clear and may be affected by the species of 
mosquito by which it is carried. 36 
Early chemotherapeutic treatment for LF relied on diethylcarbamazine (DEC), a 
synthetic organic compound, still in use for LF, which targeted a range of parasitic 
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infections but which was contraindicated in areas where onchocerciasis was co-endemic 
because DEC can cause eye damage in infected persons. Ivermectin, used to control 
onchocerciasis, is also effective against rnicrofilariae and can be used effectively in areas 
with co-endemicity. Both DEC and ivermectin kill microfilariae, but their effects on 
adult worms are not clear. It is believed that a drug that could kill adult worms would 
have a greater effect on control efforts and, in fact, DEC may have some effect on 
them.30•33 Ivermectin, however, has been shown in studies not to kill adult worms.37 
Albendazole has been used since the 1980s to treat intestinal parasites and since 
the 1990s to treat LF. The effects of albendazole on LF are an issue of debate: the WHO 
suggests that albendazole kills or sterilizes adult worms and studies have shown a 
beneficial effect of co-administration with DEC and albendazole.38•39 However, a 2009 
Cochrane review suggested that albendazole has little or no effect on its own and only a 
small beneficial effect when taken in combination with ivermectin, but the authors 
acknowledge that their findings are inconclusive.36 Popular opinion, however, maintains 
the drug combination's macrofilaricidal effect and current WHO guidelines continue to 
recommend a combination of albendazole/DEC or albendazole/ivermectin for mass 
treatment of LF. 
In 1998, the pharmaceutical company, GlaxoSmithKline, formed a partnership 
with the WHO to eliminate LF by committing to provide albendazole free of cost to 
every country at risk for as long as necessary to eliminate the disease as a public health 
problem. Tllis partnersllip, in combination with the Mectizan (ivermectin) Donation 
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Program supported by Merck & Co. begun in 1987 to eliminate onchocerciasis and later 
expanded to include LF, now ensures availability of the albendazole/ivermectin drug 
therapy globally. 
1.3 Soil Transmitted Helminthiasis (STH) 
Characteristics & Transmission 
STHs are a group of intestinal worms that infect humans and are among the most 
common infections worldwide. The causal agents in humans are any of intestinal lumen 
dwelling nematodes: Ascaris lumbricoides (roundworm), Trichuris trichiura 
(whipworm), or Ancylostoma duodenale, and Necator americanus (hookworms). While 
the outwardly visible signs of STH infection are limited, the developmental effects on 
children can be severe. 
Transmission of soil-transmitted helminths occurs through feces. Eggs from the 
adult females are passed into the environment in feces where they become infective 
within days (hookworm and whipworm) or weeks (roundworm). Once in the 
environment, infective eggs are passed either by ingestion of fecally contaminated food 
or water (Ascaris and Trichuris) or through penetration of skin by larvae (Ancylostoma 
and Necator). The infective eggs of the whipworm hatch, mature, mate, and lay eggs in 
the intestines within 70-90 days. Both the roundworm, once hatched, and hookworm will 
migrate through the circulatory system until they reach the lungs. From there, they pass 
through the trachea and mouth where they are ingested. They then mature, mate, and 
release eggs within 6-8 weeks. 
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Heavy infections result in blood loss leading to increased risk of anemia and 
hypoproteinemia, which, in children, can lead to poor physical and developmental growth 
causing stunting and decreased mental acuity. In adults, this may reduce productivity. In 
some cases, pulmonary complications can occur caused by the migration of roundworm 
or hookworm larvae through the lungs and in the case of Ascaris, bowel obstructions can 
occasionally lead to death. 
Disease Burden 
It is estimated that more than 2.5 billion persons are infected with at least one of 
the STH species of parasite with the greatest number of infected persons living in sub-
Saharan Africa, the Americas, China, and East Asia.40•41 
STHs are most commonly found in warm, moist climates where sanitation and 
hygiene are poor. This includes more temperate climates during warmer seasons. While 
adults are susceptible to morbidity due to infection, the greatest risks are seen in children 
due to their developmental life cycle. 
Identification 
Identification of STH infection is determined by stool examination and the 
presence of eggs in feces. The Kato-Katz Technique is a method used to stain stool 
samples and then examine them under microscope to identify eggs. Eggs are then 
counted to calculate the mean eggs per gram. A similar analysis called Formol-Ether 
Concentration Technique takes a larger sample and separates out the eggs from the fecal 
matter. While more sensitive to infection, this technique is more labor intensive and 
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costly than the Kato-Katz technique. 
Treatment 
Early treatment of intestinal worms focused on either purgatives to expel worms 
or toxins to kill the worms. In the early part of the 19th century, turpentine oil was a 
common treatment as were various extracts of figs, ferns, and garlic were given either 
orally or via enema. In the early part of the 20th century, a number of compounds were 
tested, several of which proved fatal. The discovery of the benzimidazole family of 
medicines in the latter part of the 20th century, led to the first safe and effective 
treatments. Thiabendazole and levamisole were among the first of these, followed later 
by albendazole and mebendazole, both of which are still in use today. A single dose of 
albendazole or mebendazole can reduce intensity of infection thereby controlling 
morbidity; ivermectin is likewise effective against Ascaris. 
Current campaigns to address STH call for twice annual treatment of school-aged 
children. GlaxoSmithKline has pledged to donate albendazole for this purpose to all 
areas needing treatment. 
1.4 Schistosomiasis 
Characteristics & Transmission 
Schistosomiasis, or bilharzia, is an infection caused by any of several trematode 
worms (flukes) of the genus Schistosoma. There are five species of Schistosoma that 
infect humans including S. mansoni, S. intercalatum, S. haematobium, S. japonicum, and 
S. mekongi. In Africa, S. mansoni and S. haematobium are predominant throughout the 
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continent while S. intercalatum is found in certain areas of central and western Africa. S. 
mansoni is also found in Latin America and the Caribbean. S. japonicum and S. mekongi 
are mostly confined to Asia and the Pacific. 
Adult schistosomes live in blood vessels draining either the bladder (S. 
haematobium) or the intestine (Schistosoma mansoni, S. japonicum, S. mekongi, and S. 
intercalatum) where females produce eggs that are passed through urine or feces. On 
contact with water, free-swimming larvae (miracidia) emerge from the eggs where they 
infect an intermediate host, a fresh water snail. Once in the snail, the miracidium then 
begins to divide, eventually producing thousands of new, infective parasites (cercariae) 
that are re-released into the water. The infective cercariae then bore through the skin of a 
human host, finding their way to the blood vessels via the circulatory system, where they 
mature over a period of six to eight weeks. 
The effects of schistosomiasis infection are caused by immunological reactions to 
eggs that are deposited in various tissues rather than passing to the outside world. The 
effect of infection depends on the location of deposited eggs such as the liver, kidneys, 
lungs and other organs. Infection ofthe colon or bladder has been associated with 
carcinomas in those organs making schistosomiasis one of the few parasitic infections 
that cause cancer. There are no outwardly visible signs of schistosomiasis infection 
except for bloody urine seen in some heavy infections of S. haematobium. Other 
symptoms can include anemia or diarrhea. Chronic infection may cause liver fibrosis , 
portal hypertension, urinary tract obstruction, heart failure, or renal failure. Like STH, 
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children are most susceptible to morbidity associated with infection but growing evidence 
is pointing towards increased risk in adults, particularly in terms of co-morbidity with 
other diseases such as malaria and HIV/AIDS .42,43•44 
Disease Burden 
The WHO estimates that as many as 700 million people are at risk of infection 
with schistosomiasis globally and that more than 207 million people are infected. 
Because of the difficulty in assessing schistosomiasis, particularly intestinal 
schistosomes, accurate estimates are difficult to obtain. 
Populations living near standing water, such as irrigation canals, and with poor 
sanitation and hygiene are particularly at risk. Infection can be quick but severe 
morbidity often requires significant infection. 
Identification 
Like STH, the intestinal schistosomes are identified through stool examination. 
Urinary schistosomiasis (S. haematobium) is identified through the presence of eggs or 
blood in the urine. A urine dipstick test for hematuria is often used to determine minute 
traces of blood. Recent antigen tests for S. mansoni have begun to be used; however the 
sensitivity of the tests has been problematic and their cost ($2.00 USD each) is too high 
for large-scale examination. 
Treatment 
Early treatment for schistosomiasis used the compound antimony, a toxic 
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chemical element, which killed the schistosome but was safe in limited doses for the 
human host. Since then, several other medicines have been developed, most notably 
oxamniquine for S. mansoni and metrifonate for S. haematobium; however, none have 
been as safe and effective as praziquantel. 
Currently, there is a significant effort being put towards the development of more 
effective drugs and a vaccine against schistosomiasis by organizations such as the Bill & 
Melinda Gates Foundation, the Sabin Vaccine Institute and the London School of 
Hygiene and Tropical Medicine. Progress, however, has been slow. In January 2012, 
Merck KGgA (the German counterpart to the U.S. Merck & Co.) pledged to donate 250 
million praziquantel tablets annually for as long as the medicine is needed. 
1.~ Global Strategies 
The WHO sets the strategies for the global approach to NTD control. In recent 
years, there have been significant changes to treatment protocols. Thresholds have been 
lowered and the target populations have grown. Evaluation units have been refined and 
programs have moved from control to elimination or a combination of both. The strategy 
for treatment depends on a number of factors including available medicines and 
technologies, life cycles of the infectious agents or their intermediate hosts, and the 
ability to implement strategies at a scale necessary to achieve whichever goals are 
targeted. Each of these factors effects integration and often are at odds with one another. 
MDA has been the one constant that has remained across all the disease programs that are 
discussed in this paper and, thus, is the focus of integrated activities. The goals and 
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objectives of each strategy are described below and the logic behind integration 
examined. 
1.5.0 Targets: Eradication, Elimination and Control 
The International Task Force for Disease Eradication was first formed in 1988 to 
evaluate the potential for eradication of more than 90 diseases, 30 ofthem in depth, and 
to identify barriers to their eradication. As part of this process, this group recognized the 
importance of developing standardized terms used to define the activities of disease 
eradication, elimination, and control and the necessary actions needed for each (see 
Annex 2 for full list of definitions).45 In summary, these were: 
Control: Reduction of disease incidence, prevalence, morbidity or mortality to a 
locally acceptable level as a result of deliberate efforts. Continued intervention measures 
are required to maintain the reduction. 
Elimination as a public health problem: Reduction to zero of the incidence of a 
specified disease or infection caused by a specific agent in a defined geographical area as 
a result of deliberate efforts. Continued intervention measures are required. 
Elimination of infection: Reduction to zero of the incidence of infection caused 
by a specified agent in a defined geographical area as a result of deliberate efforts. 
Continued measures to prevent re-establishment of transmission are required. 
Eradication: Permanent reduction to zero of the worldwide incidence of infection 
caused by a specific agent as a result of deliberate efforts. Intervention measures are no 
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longer needed. 
The WHO has adopted these definitions and set global policy on how these goals 
can be achieved. Onchocerciasis has recently moved toward elimination of infection in 
some, but not all areas of Africa. LF has been an eradication program since 1999 and a 
target date of2020 has been set for global eradication. STH has been a control program 
with a particular focus on children, and recent debate on moving schistosomiasis to an 
elimination program has pushed the World Health Assembly to adopt a resolution 
pushing for greater effort in stopping the disease. 
1.5.1 Onchocerciasis 
The life cycle of 0. volvulus and its intermediate host have dictated the global 
strategy to combat onchocerciasis. Prior to the introduction of ivermectin, control 
strategies focused on vector management of the intermediate black fly host. During the 
1970s and 80's, the WHO's, Onchocerciasis Control Program (OCP) implemented 
intensive vector management programs in 11 countries in Africa where the vectors were 
geographically isolated enough that larviciding could effectively eliminate the black fly, 
thereby halting transmission. While this strategy was effective at stopping transmission 
as long as active control was in place, the fact that the adult worms continued to produce 
microfilariae throughout their lifetime meant that reintroduction of the black fly vector 
was a constant threat, particularly in areas which neighbored non-program areas. The 
introduction of ivermectin provided a safe and effective means for the control of 
microfilariae and was added to the OCP in 1988, paving the way for elimination in 10 of 
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the 11 countries under the OCP by 2002. 
In the remaining onchocerciasis endemic countries, a new strategy to control 
morbidity using mass treatment with ivermectin was started in 1995. In Africa, APOC 
was created that same year to oversee the implementation of the new control programs. 
At that time, it was not clear whether ivermectin treatment alone could effectively 
eliminate transmission of the disease. It was understood that the drug, given on an annual 
basis, could kill off circulating microfilaria but did not immediately affect adult worms. 
The potential for elimination, therefore, was theorized but not made a goal of the APOC 
strategic plan. 
Figure 1 is an elimination curve showing a graphical representation of the 
theoretical phases of elimination targeting microfilaria. The x-axis represents time while 
the y-axis represents the total infection rate. During Phase 1, as microfilaricidal medicine 
is administered and microfilaria are killed off, the number of infections found in the 
intermediate host vectors begins to decline; this is called the annual transmission 
potential (ATP). Once the A TP reaches 0, there is no longer active transmission and 
Phase 2 begins. During this phase, the adult worms continue to live and reproduce until a 
point is reached where the remaining adult worms can no longer sustain a population 
growth. Once the adult worm population reaches this point, Phase 3 is reached and MDA 
can stop. At this point a period of post treatment surveillance is needed before 
confirmation of elimination of transmission, phase 4, can be claimed. 
A few countries, mostly in the Americas, have been able to achieve phase 3 using 
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ivermectin treatment alone by providing multiple treatment rounds per year.46'47 In 
Africa, at least two countries have managed to eliminate the disease in certain foci using 
once annual treatment while others have managed to achieve success with twice annual 
treatment.48'49 Other countries, however, have not been as successful and transmission 
continues despite more than a decade oftreatment.50'51 Despite these challenges, APOC 
and the WHO have recently made a shift from a control program to an elimination 
program. 52 The exact strategy to be used to achieve this, however, has yet to be 
determined. The dominant push is to move from once annual to twice annual treatment 
in highly endemic foci, problem zones, and new programs. 
1.5.2 Lymphatic filariasis (LF) 
In 1993, the International Task Force for Disease Eradication included LF as one 
of the diseases that could potentially be eliminated using currently available tools. 
Unlike onchocerciasis, the drug combination of ivermectin with albendazole has been 
effective as both a micro- and macrofilaricide. For this reason, the disease was also 
labeled as potentially eradicable using the same elimination curve as the onchocerciasis 
program. Until recently, the only elimination strategy that had formally been 
implemented was in the WHO Pacific region where disease management was largely 
contained. In 2011, the WHO published new guidelines for global LF elimination.53 In 
these guidelines, the WHO calls for elimination of LF by 2020 using annual mass 
treatment. It is estimated that once countries implement this plan, it will take up to 8 
years to achieve elimination before post treatment surveillance can begin. 
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1.5.3 Soil Transmitted Helminthiasis (STH) 
The strategy for STH is currently as a control program. The focus of treatment 
campaigns is to reduce morbidity among children through twice annual treatments using 
antihelminthic medicines. Targeted administration of albendazole, mebendazole or 
levamisole is the recommended strategy to keep morbidity in check. The intensity of 
infection dictates the frequency of treatment with higher endemic areas receiving two or 
more treatments annually. 
1.5.4 Schistosomiasis 
Schistosomiasis is currently listed as a control program. In November of2011 , 
however, an expert committee was assembled as an informal consultation on 
schistosomiasis to review the current guidelines for treatment and to make 
recommendations for improving the current strategy. The subsequent report was used to 
draft a new strategic plan in which elimination of schistosomiasis is now a goal. At the 
same time, a report by the secretariat to the WHO executive board entitled "Elimination 
of Schistosomiasis" has called for all schistosomiasis-endemic countries to, "intensify 
control interventions an strengthen surveillance, with the aim of eliminating the 
disease. "54 The new strategic plan calls for intensified treatment with praziquantel in 
areas of high mtensity and in problem areas or hot spots. While this is not clearly 
defined, twice annual treatment is suggested as a possible means of intensification·. 
1.6 Integration 
Each NTD protocol has a unique approach to achieving the goals laid out by the 
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WHO. These approaches may have divergent goals or conflicting strategies and so it is 
not always possible to fully integrate all activities needed. For example, onchocerciasis 
and LF are mapped and monitored at the district level using a sample population to 
represent infection in the total population while schistosomiasis and STH need to be 
measured at the community level using children as a proxy for the total population. STH 
and, in some cases, onchocerciasis programs use semi-annual treatments while 
schistosomiasis and LF programs use annual treatments. LF and onchocerciasis aim to 
stop transmission in the vector while STH and schistosomiasis focus on stopping 
infection in the human host. Thus, it is not always possible to integrate all aspects of a 
program aimed at treating NTDs. For these reasons, the calls for integration have 
focused almost entirely on MDA and its associated activities (training, community 
mobilization, etc.). Given that this is the most appropriate point for integrated activities, 
it is surprising that the empirical evidence to support this is lacking. We will explore this 
further in the next section. 
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2. Costs Analysis of MDA 
As will be seen, the existing literature does report that average treatment costs fall 
as the size of the program expands due to economies of scale for MDA programs. To 
date, however, little or no literature exists that evaluates possible costs savings from 
integrating programs and no studies have examined the costs of the TDA program 
implemented in Nigeria or elsewhere. These CO!fclusions are based on a literature review 
conducted for this dissertation using PubMed and any ofthe key terms of MDA, 
onchocerciasis, LF, schistosomiasis, or helminthiasis with the term cost. The search 
yielded a total of 2,028 unique articles published between 1956 and December 2011. 
Relevant articles were selected based on whether actual program cost data were used as 
opposed to theorized costs, and whether a cost per treatment could be ascertained for 
comparison. Of the 2,028 articles published, only 19 met the criteria for review. Three 
of these were reviews that compiled data from other publications, one was a re-
publication of data presented in a different journal and another did not present data in US 
dollars or provide an exchange rate or date of distribution. The remaining 14, published 
between 1998 and 2011 , were reviewed to assess costs and treatments achieved 
(effectiveness) of various MDA programs. 
Table 1 is a summary ofthe atiicles reviewed. Data were reported on a total of39 
MDA programs in 16 countries. Nine of the MDA programs reviewed were either partly 
or completely facility based and five used mobile health teams or medical staff, both of 
which drove costs higher than their school or community based counterparts because of 
32 
high personnel costs. Three of the papers did not separate the cost of drug (most of 
which are now donated). To account for this, drug costs were estimated in those 
countries based on the 2002 and 2006 WHO estimation of average drug dose costs 
(Annex 3).55 All costs per treatment have been adjusted to 2012 costs based on the 
Consumer Price Index. Treatment delivery costs (not including the drug) ranged from a 
low of 0.01 cent per treatment in Vietnam to a high of $3.33 per person in Egypt. The 
mean cost per treatment was 0.83 cents. Economies of scale were seen in Vietnam where 
startup and delivery costs dropped from 0.68 to 0.01 cents per treatment as the treatment 
number rose from 120,000 in 2000-2001 to 2.7 million in 2005-2006. In Egypt, medical 
doctors and nurses traveled to each school to provide treatment, thus raising expenses due 
to the high personnel costs needed. Similar economies of scale as Vietnam were seen in 
Burkina Faso, Tanzania, and Egypt as the number of treatments increased. 
None of the articles identified in this literature review compared the costs of 
integrated versus stand-alone programs for the same set of drug treatments (and no 
information was provided on the structure of costs). Thus, previous research has not 
addressed specifically the 'stand alone' program (ivermectin + albendazole separate from 
praziquantel) as compared to the integrated program (ivermectin + albendazole + 
praziquantel. 
Comparing stand-alone programs to the integrated programs identified in this 
literature review is impossible because the studies do not provide comparative or 
longitudinal data showing cost savings associated with the two strategies. Integration 
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was not common and only six of the 39 programs (15%) targeted more than one disease. 
To compare integrated with stand-alone distributions, data from programs from 
schistosomiasis and STH distributions were used to compare costs. The average delivery 
cost per person for the six integrated MDA rounds was compared with the cumulative 
averages of the stand-alone rounds for each of the two diseases (i.e. mean STH MDA + 
mean schistosomiasis MDA). All six of the integrated programs were either school-
based or a combination of school- and community-based distributions. Ofthe nine 
distributions for STH alone, seven were either school or community-based. One of these, 
however, included capital start up costs and was not counted here as the other sources did 
not include these costs. Only two stand-alone distributions for schistosomiasis were 
recorded. One of these presented the cumulative average of a 1 0 year program and 
included capital costs while the other was conducted by a mobile health team which is 
generally recognized as more costly than the community or school-based alternatives due 
to high personnel costs. 56 However, for the sake of comparison, the distribution using the 
mobile health team is used here. 
Table 2 shows the comparative average cost of integrated schistosomiasis and 
STH programs compared to stand-alone distributions. The mean cost for integrated 
delivery of albendazole with praziquantel was 0.25 cents. For stand-alone distributions 
targeting STH, the mean cost of distribution was 0.10 cents. For the single distribution of 
praziquantel for which data was available, the cost was 0.32 cents. The combined cost to 
deliver two rounds of treatment, therefore, would be 0.42 cents. Thus, in this case, the 
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integrated delivery of medicines suggests a savings of 40%. 
While this comparison may provide some insight into the potential for cost 
savings for integration, it is highly problematic. First, it uses data from 10 districts in 
seven different countries over a period of 10 years. Second, the data on praziquantel 
MDA were limited to a single distribution using mobile health teams. Finally, the 
distribution methods utilized differing distribution strategies. The utility of this 
comparison is also limited: these costs do not identify inputs, activity costs, or resource 
allocation. They thus provide no information that might be used for program planning or 
sustainability save for a base cost. 
Assessment of cost is a key component to understanding the benefits and 
limitations of integration. To assess these, both cost and treatment data are needed. Cost 
data are a critical component of understanding sustainability and for planning. A clear 
understanding of the activities conducted and the support needed to carry them through 
help to determine where resources need to be allocated. Treatment data help measure 
both efficacy and expected output of a program. The remainder of this paper is dedicated 
to examining the costs associated with MDA and the treatment data of a program 
targeting these diseases. 
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3. Program Analysis 
The contiguous states of Plateau and Nasarawa are located in north-central 
Nigeria with an estimated 4.1 million residents. Nasarawa was formed from Plateau in 
1997 and the population of the two states is predominately Hausa speaking with 
approximately 80% living in rural, agricultural settings. The two states are divided into 
30 administrative units called Local Government Areas (LGA). Since 1992, The Carter 
Center has assisted the state ministries of health in providing MDA with ivermectin for 
the control of onchocerciasis in 12 LGAs. In 2000, programs for both LF and 
schistosomiasis were started. For LF, treatment started in the 12 LGAs endemic for 
onchocerciasis and was expanded to all 30 LGAs by 2003. Schistosomiasis was started 
in 5 LGAs but did not achieve full coverage of all 30 LGAs until 2008 when 
WHO/Merck donated enough praziquantel to cover the two states. 
In 2008, 14 LGAs that had received praziquantel prior to the WHO/Merck 
donation were able to start TDA. This was followed by eight additional LGAs (5 in 
Plateau and 3 in Nasarawa) that transitioned from stand alone treatment rounds in 2008 to 
TDA rounds in 2009 and are reviewed here for this study. Six of the eight LGAs were 
rural and the remaining two were urban (one in each state). These LGAs ranged in size 
from roughly 120,000 to 500,000 persons. All eight LGAs had received ivermectin and 
albendazole treatments for at least 7 years prior to the study and two of the eight had 
received some praziquantel as a separate treatment between 1999 and 2005. 
Volunteer community directed distributors (CDDs) selected by community 
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members for this purpose were responsible for distributing medicines. All CDDs were 
trained in providing health education, proper dosing, record keeping, and monitoring for 
adverse events. Volunteer supervisors were also trained to provide oversight and support 
to CDDs, monitor drug use, and to provide summary records of drug treatments. One to 
two weeks prior to distribution, community mobilization took place in order to alert 
communities to the upcoming treatments and to encourage participation. In most cases, 
CDDs carried medicines door-to-door but in some instances central-point distributions 
(i.e. from a he?Jth post, village square, school, etc.) were used. 
3.1 Methods 
Treatments were calculated as the total number of doses provided, for both 
praziquantel and for ivermectin with albendazole, while treated individuals (children or 
adults) were calculated as the number of persons receiving any treatment. CDDs used 
height poles (color labeled for ivermectin and praziquantel) to provide dosing based on 
height as a proxy for weight. Treatments were designed to provide approximately 
150!-lg/kg of ivermectin and 40mg/kg of praziquantel. In 2008, all persons >90cm and 
above received a stand-alone round of ivermectin with a single 400 mg albendazole 
distributed by a CDD. One or more weeks later, the same CDDs delivered praziquantel 
to all school-aged children (height >94cm up to the age of 15 years). During 
distribution, MOH and Carter Center Staff provided supervision and assistance as 
necessary to ensure safety, proper recording and treatment quality. The treatment eligible 
population excluded persons below proper height or age, pregnant women, lactating 
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women in the first week after birth, and persons who were chronically ill. Coverage was 
expressed as a percentage and calculated as the number of persons treated/number 
treatment eligible X 100. 
In 2009, CDDs treated all eligible school-aged children with all three medicines 
as TDA while adults received only ivermectin with albendazole. The same dosing 
methods as described above were followed, but now with praziquantel also given to 
children >94 ern to 15 years of age together with the other medicines. 
Each CDD maintained a register of every household and its members in their 
designated area. These registers were updated regularly and all new arrivals (births, in-
migration) and departures (deaths, out-migration) were recorded. Each page of the 
register was dedicated to a single household where the names, occupation, sex, age, and 
(as appropriate) pregnancy status of all household members were recorded. During 
distributions, each eligible person was recorded as having received or not received 
medicines, the total dose given, and whether the medicine was refused. For 48 hours 
after treatment, the CDDs monitored for adverse events such as headaches, abdominal 
pain, or fever and provided analgesics (paracetamol) if necessary. Severe adverse events 
were to be referred to a clinic or hospital. All adverse events were recorded in the 
register and reported to the CDD supervisor. 
The cost analysis focused on costs of conducting the MDA program to the MOH 
and The Carter Center. These costs included salaries, transportation, supplies, per diems, 
and intervention materials (i.e. treatment registers, analgesics, etc.) . Operational data 
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were also collected in terms of specific activities that were used to allocate salary time 
devoted to those activities. These costs, referred to as activity costs, included advocacy, 
data management and reporting, drug delivery and distribution, field supervision, health 
education and community mobilization, procurement, and training. 
Costs were calculated as MOH costs and Carter Center costs. The MOH provided 
personnel but no other direct funding to the MDA program. To calculate the value of 
staff salaries to the MDA program, different staff positions and salaries were 
documented, and MOH field activities were monitored through employee work logs. A 
sample of 26 MOH field staff (out of a total of 95 field staff) consisting of different 
positions (e.g., field supervisor, field officer, etc) were selected and rotated monthly. 
Those selected were asked to complete a detailed retrospective work log for the month. 
Work logs included specific activities performed for each ofthe MDA interventions, the 
amount of time spent on these activities, whether the activities were considered integrated 
or stand-alone, whether there was any out-of-pocket expense or if per diems were paid. 
These were then used to create an average number of days worked per MDA intervention 
and each activity; this average was then applied to all field staff in that LGA. Time was 
converted to money by multiplying the daily average field staff employee salary of each 
LGA by the average number of days worked (i.e. annual paid work days) in that LGA to 
determine the cost of the employee inputs spent on specific MDA related activities for 
each LGA. 
Since The Carter Center provided all direct fmancing, MDA program costs could 
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be monitored through examination of Carter Center financial records. These accounts 
were manually separated according to activity and distribution. Input costs were then 
categorized according to the type of input: per diems, transportation, and materials and 
supplies. Separate financial records were kept for praziquantel treatment and 
ivermectin/albendazole treatment rounds in the stand-alone year (2008) for all 8 LGAs. 
In the TDA year (2009), the integration of drug delivery meant that these costs were not 
broken out separately (by treatment round) as all three drugs were administered together 
to the target population. We determined costs for each LGA, and total costs, for both 
drug distribution strategies. When appropriate, we calculated the separate costs for 
delivery of drugs to specific target populations (school aged children for praziquantel 
versus total population for ivermectinlalbendazole). 
During the 2008 MDA, since only children received praziquantel, costs were 
calculated as the overall average cost per treatment (total program cost/number of 
treatments of ivermectin with albendazole + treatments of praziquantel) and average cost 
per child treated ([total program cost ivermectin and albendazole /persons treated with 
ivermectin and albendazole] +[total cost stand alone praziquantel round/children treated 
with praziquantel]. 
During TDA, all medicines were co-administered and therefore separate costs (i.e. 
overall average cost and cost per child) could not be assessed. For sake of comparison of 
children between stand alone and TDA distributions, 2009 TDA praziquantel treatments 
are calculated as a separate treatment delivered; in other words, children receiving TDA 
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were counted as two treatments to give the denominator for calculating the cost per child 
treated [total cost/(treatments in children X2)] while adults were counted as only a single 
treatment. 
All costs presented are delivery costs only and do not include overhead costs such 
as rent, utilities, Carter Center headquarters costs, etc. Carter Center field staff salaries 
averaged $172 USD per LGA per year for MDA related activities (<$0.001 per 
treatment) but were considered administrative overhead and were not included in the 
delivery costs. In-kind reimbursements, if any, paid to CDDs by their communities were 
determined by the community involved and were also not included in the analysis. 
Finally, the value of the donated medicines was a fixed cost and was not included. 
Statistical analysis was done using STAT A 11. A two-sample t-test was used to 
compare mean LGA costs and per person and per treatment costs from stand alone 
distributions to TDA. A P-value of <0.05 was considered statistically significant. Mean 
costs and P-value are presented. 
3.2 Results 
During the 2008 stand alone distribution, 1,301,864 treatments of 
ivermectin/albendazole were given during round 1, and 279,505 treatments of 
praziquantel were given to children in round 2. This represented 100% and 90% 
coverage of the eligible population for the respective drugs. During the 2009 TDA 
distribution, 1,297,509 ivermectin/albendazole treatments were given to all eligible 
persons (children and adults) and 299,078 praziquantel treatments were co-administered 
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to children as TDA. This represented 100% and 98% coverage of the eligible population. 
Total number of treatments (ivermectin/albendazole + praziquantel) remained relatively 
constant during the two years: 1,581 ,369 and 1,596,587 treatments respectively (Figure 
2). The total MDA costs for the 2008 stand alone distributions were $123 ,624: $66,139 
for delivery ofivermectin/albendazole and $57,485 for praziquantel, with a mean cost per 
LGA of$15,453. In 2009, the TDA approach reduced the total MDA cost by 41.1% to 
$72,869 (Figure 2). Minor adverse events (headaches, abdominal pain, or fever) were 
reported in 0.06% and 0.02% of the population in 2008 and 2009 respectively. No severe 
adverse events were reported. 
Total treatments and cost by LGA and by input are shown in Table 3. The mean 
cost per LGA decreased significantly ($6,344) from the stand-alone distribution 
($15,453) to the TDA distribution ($9,109, p<0.01). The total cost per treatment for all 8 
LGAs decreased by $0.03 from $0.08 in 2008 to $0.05 in 2009. During the stand-alone 
distribution, the total cost to deliver ivermectin with albendazole was $0.05 and for 
praziquantel was $0.21 giving a total cost of $0.26 per child treated. Counting children 
as two treatments in 2009 gave a cost per child treated of $0.1 0, a reduction of $0.16 
from the previous year. The mean LGA cost per treatment decreased by $0.04 from 
$0.10 to $0.06 (p>O.OS). The mean LGA cost to treat children reduced significantly 
($0.22) from the stand-alone distribution ($0.34) to TDA ($0.12, p<O.Ol). 
Economies of scale occmTed in both distribution strategies. Figure 3 shows that 
as treatment numbers increased the cost per treatment in each LGA decreased in both 
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2008 and 2009. Economies of scope, changes in costs due to co-administration and 
integration, were greatest in LGAs with smaller populations and fewer treatments while 
the LGAs with populations nearing 400,000 saw much less differentiation. Thus, LGAs 
with smaller populations saw the greatest proportion of cost savings in the transition from 
stand alone to TDA while larger LGAs saw smaller returns. 
Total and mean input costs of per diems, transportation, and salaries decreased 
significantly (p<0.01) from 2008 to 2009 with the exception of materials and supplies 
which saw a slight but significant (p<0.05) increase during 2009 (Table 4). This was due 
to the addition of radio and television spots promoting program activities during the year 
TDA was implemented. Salaries represented the majority of costs accounting for 75.5% 
and 72.3% of the total costs in 2008 and 2009 respectively. The mean cost of per diems 
decreased 43.7% from $2,530 to $1 ,424, p<0.01 ; mean cost oftransportation dropped 
49.3% from $922 to $467, p<0.01; and mean salaries 33.4% from $3 ,788 to $$2,522, 
p<0.01; and the mean cost of materials and supplies increased 87.8% from $336 to $631 , 
p<0.05. 
Total activity costs also decreased between the 2008 stand alone distribution and 
the 2009 TDA distribution (Table 5). Again, however, the majority of cost savings came 
from reductions in salary costs. Without the input of salaries (program expenses only), 
mean activity costs per LGA reduced significantly only for drug delivery (38 .5% from 
$1,624.34 to $999.23 , p<0.05) and for supervision (53.2% from $1 ,048 .09 to $490.50, 
p<0.01). Activity costs were unchanged for advocacy (from $398.96 to $277.92, p=NS), 
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data management (from $48.72 to $31.92, p=NS), training (from $492.29 to $456.93, 
p=NS), and health education (from $175.23 to $265.86, p=NS). 
3.3 Discussion 
This study showed that co-administration of the drugs ivermectin, albendazole, 
and praziquantel (TDA) can be effectively administered at a significant cost savings over 
the traditional stand-alone distributions. Integrating MDA programs for these three drugs 
saves significant amounts of time and resources, and speeds the delivery process to those 
in need. The most significant savings were seen in personnel costs (salaries and per 
diems). Significant savings also occurred in other major input categories including costs 
oftransportation, monitoring and supervision, and treatment. Using community directed 
interventions, the stand-alone and triple-drug MDA programs in Nigeria safely achieved 
close to 1 00% coverage of the treatment eligible population with no serious adverse 
reactions. 
The 2006 PCT guidelines for MDA treatment of multiple NTDs provide options 
for programmatic approaches, including a template for launching TDA. The guidelines 
call first for one to two separate, stand-alone rounds ofMDA, before moving on to TDA 
treatment. This is because co-administration of the drugs is not without its risks in drug 
na'ive populations, particularly ones with heavy worm burdens. 17 Relatively high rates of 
adverse events, including the concern for potentially serious adverse reactions, could 
occur in persons with high worm loads as a result of the rapid kill-off of parasites in the 
initial round of treatment. For that reason, stand-alone treatments are recommended for 
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at least the first treatment round to reduce the community worm load. The necessity of 
administering at least one round of stand-alone treatment in drug naive populations 
means that start-up costs of an MDA program considering TDA will be significantly 
higher than subsequent running costs. However, we realized a savings of 41% in the 
second year of treatment by integrating treatments; these savings of course will vary 
between programs. In our particular case, cost reductions were seen in a number of 
categories: salaries played the largest role in cost savings accounting for roughly three 
quarters of all expenses, decreasing by 43.4% during TDA. Transportation costs, not 
surprisingly, dropped by 49.4% since travel was reduced by half. Generally, activity 
costs, not including salaries, decreased from 30% to 53%. The input category of 
Materials and Supplies and the activity category of Health Education, however, increased 
due to the added expense of television and radio promotional materials during the TDA 
year of distribution; these costs were non-recurrent and would presumably be lower 
during subsequent years. Other costs, such as training and supervision, might also 
decrease over time as the experience of CDDs grows and their skills improve. 
Further cost savings were achieved with economies of scale. For both treatment 
rounds, the total costs per person treated in a given LGA decreased as the number of 
treatments required by that LGA increased; as the number approached 400,000 
treatments, the difference in costs between stand alone and TDA distributions became 
negligible. 
The cost per treatment calculations reported here included a fraction of all costs 
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needed to deliver this MDA program, and so our report is an underestimation of overall 
programmatic expenses. Overhead costs to the MOH or Carter Center, donated drugs 
costs, and the cost of the time ofthe CDDs were not included in this analysis, nor was the 
remuneration they often received that was determined and provided by their respective 
communities because these were fixed costs and tended to mask the effect of integration. 
Currently, the per-tablet cost reported by the manufacturers for ivermectin is 
approximately $1.50, for albendazole $0.19, and for praziquantel $0.08. The average 
number of tablets used per treatment in Nigeria was 2.8 for ivermectin (average cost, 
$4.20), 1.0 for albendazole (average cost, $0.19), and 1.7 for praziquantel (average cost, 
$0.14 ). Therefore, in 2008, the total market value of the medicines administered was 
$5,754,314 (ivermectin $5,467,829; albendazole $247,354; and praziquantel $39,131), 
which was more than 46 times the reported costs needed to deliver the drugs by stand 
alone methods. Similarly, in 2009, the total market value for medicines delivered was 
$5,737,936, (ivermectin $5,449,538; albendazole $246,527; and praziquantel $41,871), 
which was 78 times the costs of delivering the drugs by TDA. All transport and 
importation costs are paid by the donor agencies. 
The combined impact of treatment with all three of the drugs, ivermectin, 
albendazole and praziquantel, goes well beyond the control of the four diseases discussed 
here. Ancillary benefits to treatment include protection and treatment of other trematode 
infections (liver and intestinal flukes) , cestode infections (tape worm), and ectoparasitic 
infections (such as scabies and lice). 
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As noted in section 2, there are challenges to implementing TDA. Each of the 
drugs, ivermectin, albendazole, and praziquantel, are shipped through separate programs 
or agencies and at different times. This results in logistical challenges (that have a cost) 
in ensuring that all three drugs are readily available for distribution at the same time. 
Waiting for a late delivery, and delaying the program from the projected treatment 
calendar, would be a potential cost to the program. 
Large scale pharmaceutical donation programs have dramatically reduced the 
costs of MDA programs, as has the development of community based MDA distribution 
structures. 57•58 New donations are scaling up STH activities, and it is hoped that more 
donations ofpraziquantel will aid in increased schistosomiasis MDA.31•59 The use of 
current MDA structures available on ground to rapidly and safely scale-up drug delivery 
avoids redundancy and duplication of effort. Integrating delivery of the drugs through 
TDA is one of the most cost-efficient means to do this. 
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4 Conclusion 
This study has shown that integrated delivery of the medicines ivermectin, 
albendazole, and praziquantel not only reduces labor and costs but is also safe and 
effective at achieving treatment goals. By co-administering these medicines we were 
able to successfully reduce costs by more than 40% after one year while maintaining 
>95% coverage with no severe adverse reactions. 
The current push to scale up treatment for NTDs and to push for elimination 
where possible presents a significant opportunity for TDA. The increased support and 
subsequent implementation of new MDA programs provides a platform upon which other 
NTDs programs can be implemented for little additional cost when compared to separate, 
stand-alone programs. This would allow for not only a shorter scale up time and reduced 
cost, but a greater impact as well. In LF alone, treatments in Africa are planned to grow 
from roughly 84 million to over 400 million during the next decade. The opportunity to 
use this platform, however, may be limited as elimination programs first scale up but then 
withdraw. 
This also means that challenges will continue to exist as elimination programs, 
such as the LF elimination efforts, provide a platform for co-administration that will not 
last indefinitely. Currently, a program treating LF has the ancillary benefit of 
simultaneously treating onchocerciasis and STH. If LF is eliminated and the support for 
LF programs is withdrawn, the question will be what treatment program will be 
expansive enough to act as a platform sufficient to maintain treatment for the other 
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control programs. Despite this challenge, co-implementation should be encouraged, as it 
will help to defer implementation costs, reduce the burden of disease, and improve the 
health of affected populations for the immediate future. 
4.1 Next Steps 
In December 2012, the London Declaration was signed by many of the key 
players in the global health arena with an interest in NTDs. This declaration was a 
commitment to eliminate those NTDs by 2020 for which medicines were readily 
available. As part of this pledge, Merk KGgA has pledged to expand its existing 
praziquantel donation indefinitely and increase the annual amount of drug available from 
25 million tablets to 250 million. With the existing commitments by Merck & Co. for 
ivermectin and GSK for albendazole, there is now ample supply available for 
distribution. In addition, international donors such as DFID and USAID have pledged to 
scale up support for campaigns aimed at distributing these medicines, though the exact 
amount to be given has yet to be announced. 
With these donations, the opportunity for expansion ofMDA programs increases 
dramatically. How these funds are used will determine how many people are able to be 
treated each year. By implementing TDA, these funds will reach much farther than by 
implementing stand-alone programs. The challenge will be in promoting the use ofTDA 
among agencies and governments who are not aware of it and in challenging established 
vertical programs that could potentially perceive this as a turf war. 
Data from this paper has already been shared in the peer review literature and 
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presented at national conferences. 6° Further advocacy is being conducted with both 
donor and technical groups such as the Bill & Melinda Gates Foundation, the 
Schistosomiasis Consortium for Operational Research and Evaluation, and the Centers 
for Disease Control and Prevention. In addition, operational research is currently being 
conducted in Uganda and Ghana exploring the implementation ofTDA.25,27 
Further research would also help in promoting greater use of integrated MD A. 
Community costs play an important part in sustainability and would help in 
understanding the impact of conducting MDA on communities and community 
distributors. Research into economies of scope and the additive effects of additional 
interventions would help to understand what limitations these volunteer structures could 
support. At present, there is research going on to assess the safety of adding 
azithromycin to ivermectin and albendazole and the prospect of moving toward 
quadruple therapy to also address trachoma is an exciting one if possible. However, the 
added technical aspects of adding antibiotic treatment to other preventive chemotherapy 
could press the limits of what a lay health worker may be able to effectively accomplish. 
The immediate challenge is now the coordination of the international and national 
programs such as the African Program for Onchocerciasis Control, the Global Alliance to 
Eliminate Lymphatic Filariasis, and the Schistosomiasis Control Initiative to better 
coordinate their action plans and to promote co-implementation in regions where the 
diseases are co-endemic. A major part of this will be in integrating funding streams to 
better support distribution programs. To this end, both DFID and USAID have visited 
Plateau and Nasarawa states to witness the TDA program first hand and the author and 
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The Carter Center continue to push for integrated delivery of medicines. Further 
coordination in terms of drug donation applications, tracking, and delivery will also help 
in the effort to promote TDA. 
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Figure 1. An elimination curve showing the decline in L3 larvae, the annual 
transmission potential (ATP), and adult worm population over time with annual mass 
drug treatment. During phases 1 and 2, transmission of the diseases is still possible. 
During phase 3, monitoring for recrudescence is necessary. 
Transmission suppressed 
to negllgi,ble levels 
Phase1 Phase2 
Adult worm population reduced 
to such low levels that it is 
irreversibly moving to its 







Source: World Health Organization, (WHO/APOC) 2010. Conceptual and operational framework of 
onchocerciasis elimination with ivermectin treatment. African Program for Onchocerciasis Control, 
WHO/APOC/MG/10.1. 
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Figure 2. The total number of treatments of ivermectin with albendazole and 
praziquantel changed little during both years of distribution but total costs reduced by 
41.1%. 
Total treatments of ivermectin with albendazole plus praziquantel 
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Figure 3. Economies of scale: a polynomial trend line shows costs per person decreased 
as the number of treatments increased by LOA for both the stand-alone (2008) and TDA 
(2009) distribution strategies. Cost savings were greatest in LGAs with fewer treatments. 
Cost per person treated compared to population 
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Table 1. Summary of publications with costs for mass drug administration (MDA) and coverage. Costs/person adjusted to 
2012 dollars (original). 
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ALB+ SCH + School Actual $0.84 $0.47 Oshish, et al. 
Yemen 2008 PZQ STH Based cost 280,976 t$221 ,697 (0.79) (0.44) 2011 61 
ALB+ SCH+ School Actual $0.70 $0.40 Oshish, et al. 
Yemen 2009 PZQ STH Based cost 319,248 t$210,704 (0.66) (0.37) 2011 
1995- Community Annual $1.16 §0.95 Croce, et al. 
Cambodia 2006 PZQ SCH Based Average $82,244 (1.02) (0.84) 201062 
Burkina IVM+ Community Actual $0.14 Goldman, et al. 
Faso 2001 ALB LF Based cost 77% 431,399 $46,000 (0.11) 200763 
Burkina IVM+ Community Actual $0.08 Goldman, et al. 
Faso 2002 ALB LF Based cost 69% 1,801,125 $110,000 (0.06) 2007 
IVM+ Community Actual $0.22 Goldman, et al. 
Ghana 2002 ALB LF Based cost 69% 1,223,122 $1,358,000 (0.17) 2007 
Facility 
Based + 
IVM+ Community Actual · $0.72 Goldman, et al. 
Tanzania 2000 ALB LF follow up cost 91% 37,000 $20,000 (0.54) 2007 
Facility 
Based+ 
IVM+ Community Actual $0.54 Goldman, et al. 
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LF Based cost 
Community Actual 
LF Based cost 
Community Actual 
LF Based cost 
$0.34 Goldman, eta!. I 
82% 437,698 $118,000 (0.27) 2007 
t$2.38 §2.29 Goldman, et a!. 
83% 115,411 $216,000 (1.87) (1.80) 2007 
t$1.08 §1.06 Goldman, et a!. 
75% 250,059 $217,000 (0.87) (0.85) 2007 
$2.97 §2.94 Goldman, eta!. 
71% 105,750 $236,000 (2.23) (2.21) 2007 
$2.54 §2.51 Goldman, eta!. 
53% 79,713 $156,000 (1.96) (1.94) 2007 
$1.66 §1.63 Goldman, et a!. 
81% 121 ,139 $158,000 (1.30) (1.28) 2007 
$1.40 §1.38 Goldman, et a!. 
79% 100,376 $110,000 (1.10) (1.08) 2007 
$0.24 §0.21 Goldman, et a!. 
81% 556,912 $105,842 (0.19) (0.17) 2007 
t$1.82 §1.80 Ramzy, et a!. 
86% 1,795,553 $2,412,000 (1.37) (1.35) 200564 
t$1.29 §1.27 Ramzy, eta!. 
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cost (0.32) Guyatt, 2003 
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cost (0.21) Guyatt, 2003 
Partnership for 
Child 
Actual $0.06 Development, 
cost (0.04) 199966 
Partnership for 
Child 
Actual $0.04 Development, 
cost (0.03) 1999 
*** 
Annual $2.00 §1.76 Xiao-N ong, et al. 
Average (1.50) (1.32) 200567 
Actual $0.17 Onwujekwe, et al. 
cost 59% 10,522 $2,156 (0.12) 200268 
Actual $0.22 Onwujekwe, et al. 










































ON Based cost 
School Actual 
STH Based cost 
School Actual 
STH Based cost 
School Actual 
STH Based cost 
School Actual 
STH Based cost 
School 
Based+ 
SCH+ Community Actual 
STH Based cost 
School 
Based+ 
SCH+ Community Actual 
STH Based cost 
School 
Based+ 
SCH+ Community Actual 
STH Based cost 
School 
Based+ 
SCH+ Community Actual 
STH Based cost 
$0.47 
76% 40,030 $11 ,778 (0.29) Kip, et al. 199869 
"$0.19 $0 .11 Phommasack, et 
96% 973,073 $189,715 (0.17) (0.10) al. 200870 
- $0.92 - $0.88 Montresor, et al. 
120,000 $85,000 (0.71) (0.68) 200771 
$0.14 $0.11 Montresor, et al. 
700,000 $75,000 (0.11) (0.09) 2007 
$0.03 $0.01 Montresor, et al. 
2,710,000 $81,000 (0.03) (0.01) 2007 
$0.13 Leslie, et al. 
78,494 (0.11) 2011 72 
$0.17 
75,535 (0.15) Leslie, et al. 2011 
$0.20 
165,116 (0.18) Leslie, et al. 2011 
$0.14 















Egypt 1999 PZQ SCH SAC) Averaged 
t cost calculated based on reported coverage and cost per treatment 
i only cost of DEC included, ALB donated 
$3.58 
89% 20,030 $52,031 (2.60) 
$3.19 
89% 20,030 $46,561 (2.32) 
~ *ALB = albendazole, PZQ = praziquantel, IVM = ivermectin, LEV = levamisole, DEC = diethylcarbamazine, MBD 
= mebendazole 
** year of original publication of distribution as reported in Guyatt, 2003 
***calculated based on 2000 RMB-USD exchange rate of8.3 
"aggregate cost of2 rounds of distribution 
-cost includes one-time mobilization and imported drug 
§ drug cost estimated according to WHO average dose 
Dcost adjustments based on Consumer Price Index 
I 
§3.33 Talaat & Evans, 
(2.42) 200073 




Table 2.t Comparison of integrated vs. stand-alone programs for schistosomiasis and soil transmitted helminthiasis, costs 
adjusted to 2012 dollars and (original cost) 
Targeted Cost cost/person 
Country Region YearofMDA *Drug disease Distribution Method Calculation 2012 (orig.) reference 
-- ~--
distributwn 
Yemen I 2008 ALB+PZQ SCH+STH School Based Actual cost $0.47(0.44) I Oshish, et al. 2011 
Yemen I 2009 ALB+PZQ SCH+STH School Based Actual cost $0.40(0.37) J Oshish, et al. 2011 
School Based + 
Niger I Gaya I 2005-2006 I ALB+PZQ I SCH+STH I Community Based Actual cost $0.13(0.11) I Leslie, et al. 2011 
School Based + 
Niger I Kollo I 2005-2006 I ALB+PZQ I SCH+STH I Community Based Actual cost $0.17(0.15) I Leslie, et al. 2011 
School Based + 
Niger Tera 2005-2006 ALB+PZQ SCH+STH Community Based Actual cost $0.20(0.18) I Leslie, et al. 2011 
I . School Based + 
Tillaberi 2005-2006 ALB+PZQ SCH+STH Community Based I Actualcost I $0.14(0.12) I Leslie,etal.2011 Ntger 
Mean I $0.25(0.23) 
Stand-alone distribuition for STH .. 
Ghana **1999 ALB STH School Based Actual cost $0.06(0.04) Guyatt, 2003 
Tanzania **1999 ALB STH School Based Actual cost $0.04(0.03) Guyatt, 2003 
Egypt **2000 DEC STH Community Based Actual cost $0.25(0.19) Guyatt, 2003 
Lao 2007 MBD STH School Based Actual cost $0.11(0.10) Phommasack, et al. 2008 
Vietnam 2002-2003 MBD STH School Based Actual cost $0.11(0.09) Montresor, et al. 2007 
Vietnam 2005-2006 MBD STH School Based Actual cost $0.01(0.01) Montresor, et al. 2007 
Stand-alone distribution for schistosomiasis 
, . • • . ......... ......... r· ., ... ,.,,.. ··~··"M.e~~ -·-··~ _ J~9.~1 . .9.<9.;QZL,_,_ .. ,,._ . .. ... ..., .. -~ ... 
I Tanzania I I **1994 I PZQ I SCH I Mobile Health Team I Actual co~ I $0.32(0.2l)-rGuyatt, 2003 I 
Mean $0.32(0.21) 
t See Table 1 (above) for list of reference symbols. 
Table 3. Total costs, mean costs, and total treatments by LGA and input category. *P<0.05 **P<O.Ol 
f--
Local Government Area 
Bass a Bokkos Jos South Kanam Kanke Karu Lafia 
Nasarawa 
total cost & treatment Egg on Total 
no. treatments 182,087 145,905 215,946 121,978 96,462 235,323 436,695 146,973 1,581 ,369 
TCC costs $4,669 $5,128 $3 ,648 $4,262 $3,399 $2,962 $2,563 $3,670 $30,301 
MOH costs $11,263 $9,654 $14,481 $11,263 $12,872 $11,263 $8,045 $14,481 $93,321 
total costs $15,932 $14,782 $18,129 $15,525 $16,271 $14,225 $10,608 $18,151 $123,624 
cost/treatment $0.09 $0.10 $0.08 $0.13 $0.17 $0.06 $0.02 $0.12 $0.08 
cost by input [mean} 
lper diems $3,149 $3,279 $2,392 $3,041 $2,116 $1,696 $1,458 $3,109 [$2,530] 
<' transport $1,104 $1,471 $1,090 $968 $1,047 $737 $501 $461 [$922] 
~ materials & supplies $416 $379 $166 $253 $237 $529 $605 $101 [336] 
00 
0 
~ salaries $11,263 $9,654 $14,481 $11,263 $12,872 $11 ,263 $8,045 $14,481 [$11 ,665] 
0\ 
....... total cost & treatment Total 
no. treatments 170,134 136,170 236,786 114,210 89,346 232,891 446,773 170,277 1,596,587 
TCC costs $3,076 $2,771 $1,869 $2,343 $2,578 $2,877 $2,628 $2,038 $20,179 
MoH costs $6,359 $5,451 $8,176 $6,359 $7,268 $6,359 $4,542 $8,176 $52,691 
total costs $9,435 $8,221 $10,046 $8,702 $9,845 $9,236 $7,170 $10,214 $72,870 
cost/treatment $0.06 $0.06 $0.04 $0.08 $0.11 $0.04 $0.02 $0.06 $0.05 
% changefrom SA 40.8% 44.4% 44.6% 43.9% 39.5% 35.1% 32.4% 43.7% 41.1% 
cost by input {mean} 
,-., per diems $1,833 $1,857 $972 $1,085 $1,485 $1,879 $1,148 $1,135 [$1 ,424] t=3.85 ** 
~ transport $409 $503 $365 $568 $708 $465 $434 $283 [$467] t=3.55 ** A 
E-< 
materials & supplies $834 $411 $533 $690 $384 $533 $1,046 $620 [$631] t=-2.95 * '-' a, 
0 
salaries $6,359 $5,451 $8,176 $6,359 $7,268 $6,359 $4,542 $8,176 [$6,586] t=5.60 ** 0 ,... 
Table 4. Total costs by input categories and year: significant reduction in mean costs 
were seen in every input category except materials and supplies which increased due to 
added promotional campaigns. Salaries accounted for nearly three quarters of total costs 
in both years. *P<0.05 **P<O.Ol 
p d' er 1ems 
2008 (SA) $20,239.37 













cost (MOH ) T ota 
$93,320.91 1 $123,622.00 
$52,690.78 1 $72,869.64 
-43.5%** I -41.05% ** 
Table 5. salaries accounted for much of the significant savings seen across all activity 
costs. Programmatic costs (without salaries) saw significant reductions in treatment 
(drug delivery) and Monitoring and Supervision costs. Health education saw a slight but 
not significant increase in program costs due to promotional campaigns. 
Total activity costs (total costs) 
Monitoring 
Data and Health 
Advocacy Management Treatment Supervision Education Training 
(P>0.001) (P>0.001) (P>0.001) (P>0.001) (P>0.001) (P>0.001) 
2008 
(SA) $12,600.54 $20,582.29 $25,039.44 $34,295.94 $13,956.84 $17,146.97 
2009 
(TDA) $7,929.72 $12,203.84 $15,173.18 $17,887.82 $8,303.95 $11 ,371.14 
Total activity costs (salaries only) 
Monitoring 
Data and Health 
Advocacy Management Treatment Supervision Education Training 
(P>0.001) (P>0.001) (P>0.001) (P>0.001) (P>0.001) (P>0.001) 
2008 
(SA) $9,408.85 $20,192.54 $12,044.67 $25,911.23 $12,554.97 $13 ,208.65 
2009 
(TDA) $5,706.37 $11 ,948.49 $7,179.32 $13,963.81 $6,177.06 $7,715.73 
Total activity costs (program costs only2 
Monitoring 
Data and Health 
Advocacy Management Treatment Supervision Education Training 
(P=O.l3) (P=0.58) (P=0.03) (P=0.006) (P=0.06) (P=0.63) 
2008 
(SA) $3,191.69 $389.75 $12,994.77 $8,384.71 $1 ,401.87 $3,938.31 
2009 
(TDA) $2,223.35 $255.35 $7,993 .85 $3 ,924.01 $2,126.88 $3,655.41 
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